"It's not better than the foreign countries I think at the moment".
Antibodies collected from the volunteers were tested in human cells in the lab and were able to stop the virus from replicating.
Three groups of 15 patients aged 18 to 55 received three different doses of the vaccine in the Phase 1 test, the complete results of which are not yet known. Testing for neutralizing antibodies is more time-consuming than other antibody tests and must be done in a biosecurity level 3 laboratory.
This initiative from the White House also means some steps in the path from research to production are being carried out simultaneously with the stated goal of reducing the time needed to make a vaccine available to the general public should it be proved effective in staving off COVID-19 infections.
In a conference call, Moderna CEO Stephane Bancel said the preliminary tests inspired confidence that mRNA-1273 has "a high probability to provide protection" against the virus. On their website, they emphasize that they are still early in the story.More news: Hydroxychloroquine: Why is the United Kingdom bulk-buying Trump's favourite drug?
The research was conducted in partnership with the US National Institutes of Health (NIH). Of the two types of antibodies, neutralizing antibodies are of definitive importance.
"It's very good news", Barouch said.
The very early data offers a glimmer of hope for a vaccine among the most advanced in development.
When most vaccines are created, Manning said, they take either the pathogen itself or a portion of the pathogen agent and directly add it to your system. "That is, it generated the kind of immune responses that should be protective, but we can't really say that for sure". The company has also not said how it plans to make money on the vaccine.
What happens in phase two? .
The Food and Drug Administration in the United States (US) gave Moderna the go-ahead for the second phase earlier this month, with the US ravaged by the virus pandemic.More news: CDC: Keep cleaning surfaces, but coronavirus mainly spreads person-to-person
The challenge is not only finding a safe and efficient vaccine, but also producing billions of doses.
Manning said this could be done by monitoring who has adverse reactions or side effects and who doesn't. "There have been some reports of people getting reinfected, so it's not really entirely clear yet how long immunity actually lasts within an individual and how variable that is across individuals".
If that's successful, then Phase Three will be granted and the vaccine can be tested on thousands of people. Moderna's experimental vaccine, mRNA-1273, which is being co-developed with the US National Institute of Allergy and Infectious Disease (NIAID), appeared to be safe after first trials on people, according to a report in The New York Times.
Moderna kicked off the early data around the vaccine race and released the first data from its phase 1 trial of SARS-CoV-2 vaccine mRNA-1273 on May 18, in conjunction with data supporting efficacy of the vaccine in mice.
Markets are souring on the COVID-19 ramifications for global economy.More news: Ravenswood McDonald's due to reopen after traffic chaos